menu
    • menu
    [{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Anti-SARS-CoV-2 polyclonal immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kedrion \/ Kedrion Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kedrion \/ Kedrion Biopharma"},{"orgOrder":0,"company":"Kedrion","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Anti-COVID IgG therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kedrion \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Kedrion \/ Columbia University"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Rabies Immune Globulin [Human]","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Kedrion IVIG","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kedrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Not Applicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Liminal BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kedrion","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Lyophilized Powder for Reconstitution","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Kedrion IVIG","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kedrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Not Applicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Kedrion","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.02,"dosageForm":"Lyophilized Powder For Injection","sponsorNew":"Kedrion \/ Kedrion Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ Kedrion Biopharma"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Kedrion","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.02,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Human Rabies Immune Globulin","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kedrion \/ Kamada","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ Kamada"}]

    Find Clinical Drug Pipeline Developments & Deals by Kedrion

    Menu

    Kedrion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rabies Immune Globulin (Human)

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kedrion Announces an Eight-Year Extension of the Distribution Agreement with Kamada in the US for Kedrab®

                            Details : The commercial agreement includes potential expansion of Kedrion's distribution of Kedrab, a Human Rabies Immune Globulin, in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products...

                            Brand Name : Kedrab

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Rabies Immune Globulin (Human)

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Rabies Immune Globulin

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the...

                            Details : The agreement aims for the distribution of Kedrab (Rabies Immune Globulin [Human]), which is indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid, in the U...

                            Brand Name : Kedrab

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 12, 2023

                            Lead Product(s) : Human Rabies Immune Globulin

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved

                            Sponsor : Kedrion

                            Deal Size : $17.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kedrion Biopharma Grows in North America As it Completes Acquisition of Prometic

                            Details : With the acquisition of Prometic, Kedrion has finalized a series of transactions with the announcement that it was acquiring the plasma purification plant at Laval in Québec, and the license to distribute the new product called Ryplazim in the United St...

                            Brand Name : Ryplazim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2021

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved

                            Sponsor : Kedrion

                            Deal Size : $17.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kedrion IVIG

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Treated in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study

                            Details : The primary efficacy objective of KIDCARES10 is to assess the efficacy of KIg10 administered to patients with PI to demonstrate that the rate of acute serious bacterial infections is less than 1.0 to provide substantial evidence of efficacy from day 1 to...

                            Brand Name : KIg10

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 13, 2021

                            Lead Product(s) : Kedrion IVIG

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Prometic Biotherapeutic

                            Deal Size : $17.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Bus...

                            Details : This acquisition would include the Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) business operated through its subsidiaries, Prometic Bioproduction Inc., the Company’s plasma-derived therapeutics manufacturing facility (“PBP”), and Promet...

                            Brand Name : Ryplazim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 23, 2021

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Prometic Biotherapeutic

                            Deal Size : $17.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Liminal BioSciences

                            Deal Size : $22.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agree...

                            Details : Kedrion will enter into an option agreement with Liminal BioSciences to acquire the remainder of the company’s plasma-derived business, as well as Plasminogen business operated through its subsidiaries including Prometic Biotherapeutics which holds the...

                            Brand Name : Ryplazim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Liminal BioSciences

                            Deal Size : $22.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved

                            Sponsor : Kedrion

                            Deal Size : $17.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kedrion enters into Agreement with Liminal BioSciences

                            Details : According to terms and conditions, the Option would grant Kedrion the right to acquire all of the shares of PBP and PBT and would entitle Liminal BioSciences to receive up to seventy percent of the net proceeds, if granted, associated with a potential FD...

                            Brand Name : Ryplazim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : Plasminogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved

                            Sponsor : Kedrion

                            Deal Size : $17.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kedrion IVIG

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KIDCARES10, First Patient Enrolled in Pediatric PI Study

                            Details : Objectives of KIDCARES10 Study, a phase III, multi-center study are to assess the efficacy, safety, and pharmacokinetics of a 10 percent intravenous immunoglobulin (IVIG) in pediatric patients aged 2 to 17 years and affected by primary immunodeficiency d...

                            Brand Name : KIg10

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 31, 2021

                            Lead Product(s) : Kedrion IVIG

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rabies Immune Globulin [Human]

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Recipient : Kamada

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human...

                            Details : The study of KEDRAB® (Rabies Immune Globulin [Human]) conducted in children was the first and only pediatric study for any HRIG available in U.S. The study met its primary objective, which was to confirm the safety of KEDRAB in the pediatric population.

                            Brand Name : Kedrab

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 19, 2020

                            Lead Product(s) : Rabies Immune Globulin [Human]

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Recipient : Kamada

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anti-COVID IgG therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Columbia University

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kedrion Biopharma forms Partnership with Columbia University Irving Medical Center to Support Development of N...

                            Details : Kedrion will supply convalescent plasma from patients who have recovered from COVID-19 to be used for the manufacturing of IgG therapy. Columbia University will test the plasma against viral proteins to check the neutralizing power of the hyperimmune Im...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 21, 2020

                            Lead Product(s) : Anti-COVID IgG therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Columbia University

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth